Eli Lilly On Thursday, its daily obesity pill achieved the company’s objectives in the first of several trials at an advanced stage, helping patients with type 2 diabetes to reduce their blood sugar and body weight and to show safety comparable to popular injections on the market.
The results of the test are among the most watched studies of the year of the pharmaceutical industry, because they bring Eli Lilly’s experimental pill closer – called Orforglipron – another not closer to becoming a new needle alternative in the booming market of weight loss and diabetes. This more practical and easier to make pill could give Eli Lilly a major advantage over Novo Nordisk And other rivals trying to enter the lucrative space.
Data on the weight loss of the pill, as well as the rates of side effects and the treatment stops, were in accordance with what certain Wall Street analysts were waiting. But Orforglipron did not succeed in the estimates of certain analysts for a key metric of diabetes.
The highest dose of the pill helped patients lose 7.9% of their weight, about 16 pounds, on average after 40 weeks. Eli Lilly also said that patients saw no plateau in their weight loss at the end of the study, suggesting that they could lose more beyond this period.
Previous studies on the pill and existing injections have shown that patients with diabetes lose less weight than those without condition, which makes it difficult to compare it to that of drugs specifically for obesity.
About 8% of patients who took the highest dose of the pill interrupted treatment due to side effects. These side effects were mainly gastrointestinal – such as nausea and vomiting – and light to moderate severity. It is estimated that 14% of those who took the highest dose experienced vomiting, while 16% and 26% had nausea and diarrhea respectively.
In a note earlier this month, TD Cowen analysts said they expected a stop rate of 9%. Other analysts said they were planning that the side effects of the pill would be slightly worse than injections, since it is taken daily instead of each week.
But the pill missed the estimates of certain analysts for a key metric of diabetes. He helped reduce A1C hemoglobin – a blood sugar measurement – on average from 1.3% to 1.6% in different doses at 40 weeks, from a starting level of 8%. This is compared to a 0.1% reduction in patients who took a placebo during the same period.
Some analysts expected a reduction of 1.8% to 2.1%, which in accordance with the results of diabetic patients who took the injection ozempic of Novo Nordisk diabetes.
However, Eli Lilly is “happy to see that our latest Incretine drug meets our expectations in terms of security and tolerability, glucose control and weight loss, and we are looking forward to additional data readings later this year,” said the CEO of the company, David Ricks, in a press release. Incredine drugs imitate certain intestinal hormones to remove a person’s appetite and regulate blood sugar.
There are seven studies at an advanced stage on the pill, including five diabetes tests and two obesity studies. The company plans to request the regulatory approval of the pill for obesity by the end of the year and diabetes in 2026.
If it is approved, Orforglipron could help more patients access treatment and mitigate gaps in the supply of popular injections on the market. The pill “could be easily manufactured and launched on a large scale for use by people around the world,” Ricks said in the press release.
The pill could also help Eli Lilly solidify its domination in the growing segment as other drug manufacturers to provide similar products on the market.
Offering the first oral version of a so-called GLP-1 could help Eli Lilly grasp an even greater share on the market for this popular weight loss class and diabetes drugs. Eli Lilly is currently about three years ahead of other drug manufacturers who develop pills, including AstrazenecaRock, Therapeutic structure And Viking TherapeuticsAnalysts told CNBC.
Some analysts expect the GLP-1 market worth more than $ 150 billion a year in the early 2030s. Oral GLP-1s could reach $ 50 billion in this total, according to some analysts’ estimates.
Eli Lilly’s pill works in the same way as the diabetes pill of Wegovy, Ozempic and Novo Nordisk, targeting a intestinal hormone called GLP-1 to remove the appetite of a person and regulate blood sugar.
But unlike these three drugs, Eli Lilly’s pill is not a peptide medicine. This means that it is absorbed more easily by the body and does not require food restrictions like Rybelsus.